Dynamic Properties of the Intestinal Ecosystem Call for Combination Therapies, Targeting Inflammation and Microbiota, in Ulcerative Colitis

Gastroenterology. 2021 Dec;161(6):1969-1981.e12. doi: 10.1053/j.gastro.2021.08.057. Epub 2021 Sep 8.

Abstract

Background & aims: Intestinal microbiota-host interactions play a major role in health and disease. This has been documented at the microbiota level ("dysbiosis" in chronic immune-mediated diseases) and through the study of specific bacteria-host interactions but rarely at the level of intestinal ecosystem dynamics. However, understanding the behavior of this ecosystem may be key to the successful treatment of disease. We recently postulated that health and disease represent alternative stable states of the intestinal ecosystem (different configurations that can exist under identical external conditions), which would require adapted strategies in disease treatment. Here, we examine if alternative stable states indeed exist in this ecosystem and if they could affect remission from ulcerative colitis (UC).

Methods: We analyzed data from a study on pediatric UC. The data reflect current treatment practice following the recruitment of treatment-naive patients with new-onset disease. Patients received personalized anti-inflammatory treatments over a period of 1 year. Stool samples at 0, 4, 12, and 52 weeks allowed an estimation of microbiota status (through 16S ribosomal RNA gene sequencing) and host inflammatory status (through the measurement of fecal calprotectin levels).

Results: We identify 4 microbiota states and 4 host states. Longitudinal data show that the improvement of inflammatory status is accompanied by an improvement of microbiota status. However, they also provide strong indications that both improvements are retarded or blocked by alternative states barriers.

Conclusions: Our observations strongly suggest that inflammation suppression should be combined with microbiota management where possible to improve the efficacy of UC treatment.

Keywords: Alternative Stable States; GI Tract; Host; Microbiota; Symbiosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Bacteria / drug effects*
  • Bacteria / genetics
  • Bacteria / immunology
  • Case-Control Studies
  • Cellular Microenvironment*
  • Colitis, Ulcerative / immunology
  • Colitis, Ulcerative / microbiology
  • Colitis, Ulcerative / therapy*
  • Combined Modality Therapy
  • Dysbiosis
  • Fecal Microbiota Transplantation* / adverse effects
  • Gastrointestinal Microbiome / drug effects*
  • Host-Pathogen Interactions
  • Humans
  • Immunity, Innate / drug effects*
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / metabolism
  • Intestines / drug effects*
  • Intestines / metabolism
  • Intestines / microbiology
  • Models, Biological
  • Remission Induction
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators

Supplementary concepts

  • Pediatric ulcerative colitis